NO20042500L - Chemokin-reseptorantagonister og metoder for anvendelse derav - Google Patents

Chemokin-reseptorantagonister og metoder for anvendelse derav

Info

Publication number: NO20042500L
Authority: NO; Norway
Prior art keywords: methods; receptor antagonists; chemokine receptor; chemokine; antagonists
Prior art date: 2001-11-21

Application number

NO20042500A

Other languages

English (en)

Other versions

NO328166B1 (no

Inventor

Jay R Luly

Yoshisuke Nakasato

Etsuo Ohshima

Geraldine C B Harriman

Kenneth G Carson

Shomir Ghosh

Amy M Elder

Karen M Mattia

Original Assignee

Millenium Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-21

Filing date

2004-06-15

Publication date

2004-06-15

2001-11-21 Priority claimed from US09/989,086 external-priority patent/US20020169155A1/en

2002-11-13 Priority claimed from PCT/US2002/036953 external-priority patent/WO2003045942A2/en

2004-06-15 Application filed by Millenium Pharmaceuticals Inc filed Critical Millenium Pharmaceuticals Inc

2004-06-15 Publication of NO20042500L publication Critical patent/NO20042500L/no

2009-12-21 Publication of NO328166B1 publication Critical patent/NO328166B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Rheumatology (AREA)
Virology (AREA)
AIDS & HIV (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)

NO20042500A 2001-11-21 2004-06-15 Chemokin-reseptorantagonister, farmasoytiske preparater inneholdende slike, slike forbindelser for anvendelse i terapi samt anvendelse av slike forbindelser for fremstilling av medikament for behandling av sykdom NO328166B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/989,086 US20020169155A1 (en)	1998-09-04	2001-11-21	Chemokine receptor anagonists and methods of use therefor
PCT/US2002/036953 WO2003045942A2 (en)	1998-09-04	2002-11-13	Chemokine receptor antagonists and methods of use thereof

Publications (2)

Publication Number	Publication Date
NO20042500L true NO20042500L (no)	2004-06-15
NO328166B1 NO328166B1 (no)	2009-12-21

Family

ID=32713949

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042500A NO328166B1 (no)	2001-11-21	2004-06-15	Chemokin-reseptorantagonister, farmasoytiske preparater inneholdende slike, slike forbindelser for anvendelse i terapi samt anvendelse av slike forbindelser for fremstilling av medikament for behandling av sykdom

Country Status (23)

Country	Link
EP (3)	EP2286811B1 (no)
JP (5)	JP4889920B2 (no)
KR (3)	KR100952767B1 (no)
CN (3)	CN1911930A (no)
AR (2)	AR037394A1 (no)
AT (1)	ATE320431T1 (no)
AU (1)	AU2002352772B2 (no)
BR (1)	BR0213633A (no)
CA (1)	CA2467672C (no)
CY (1)	CY1107243T1 (no)
DE (2)	DE60209937D1 (no)
DK (1)	DK1448566T5 (no)
ES (2)	ES2396186T3 (no)
IL (3)	IL161669A0 (no)
MY (2)	MY142646A (no)
NO (1)	NO328166B1 (no)
NZ (3)	NZ532827A (no)
PL (2)	PL217918B1 (no)
PT (1)	PT1448566E (no)
SG (2)	SG165152A1 (no)
SI (1)	SI1448566T1 (no)
TW (1)	TWI308568B (no)
ZA (1)	ZA200403530B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2396186T3 (es) *	2001-11-21	2013-02-19	Millennium Pharmaceuticals, Inc.	Antagonistas de receptores de quimioquinas y métodos de uso de los mismos
US7541365B2 (en)	2001-11-21	2009-06-02	Millennium Pharmaceuticals, Inc.	Chemokine receptor antagonists and methods of use therefor
TWI291467B (en) *	2002-11-13	2007-12-21	Millennium Pharm Inc	CCR1 antagonists and methods of use therefor
CN101878199B (zh) *	2007-12-03	2013-09-18	诺瓦提斯公司	用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1，2-二取代的-4-苄基氨基-吡咯烷衍生物
PE20091057A1 (es) *	2007-12-19	2009-07-20	Lilly Co Eli	Antagonistas del receptor mineralcorticoide y metodos de uso
CN104292142B (zh) *	2013-07-17	2019-05-14	天津大地康和医药技术有限公司	一种n-芳基杂环丁烷脱芳基方法
CN105237455A (zh) *	2015-10-14	2016-01-13	湖南华腾制药有限公司	一种3-取代氮杂环丁烷的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DD80449A (no) *
JPS5250634B2 (no)	1971-08-23	1977-12-26
JPS61152673A (ja)	1984-12-26	1986-07-11	Kyowa Hakko Kogyo Co Ltd	ジベンズ〔ｂ，ｅ〕オキセピン誘導体の製造法
US5089496A (en)	1986-10-31	1992-02-18	Schering Corporation	Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
AU629835B2 (en)	1988-04-28	1992-10-15	Schering Corporation	Novel benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use
WO1992020681A1 (en)	1991-05-23	1992-11-26	Schering Corporation	Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
EP0524784A1 (en)	1991-07-23	1993-01-27	Schering Corporation	Benzopyrido piperidylidene compounds as PAF antagonists
EP0669979B1 (en)	1992-11-10	2005-10-12	Genentech, Inc.	C-c ckr-1, c-c chemokine receptor
AU5270796A (en) *	1995-04-07	1996-10-23	Novo Nordisk A/S	N-substituted azaheterocyclic carboxylic acids and esters th ereof
PL327445A1 (en) *	1995-12-15	1998-12-07	Novo Nordisk As	Novel process
DK1049700T3 (da) *	1998-01-21	2006-02-20	Millennium Pharm Inc	Kemokinreceptorantagonister og fremgangsmåder til anvendelse deraf
US6509346B2 (en) *	1998-01-21	2003-01-21	Millennium Pharmaceuticals, Inc.	Chemokine receptor antagonists and methods of use therefor
EP1109815A1 (en) *	1998-09-04	2001-06-27	Millennium Pharmaceuticals, Inc.	Chemokine receptor antagonists and methods of use therefor
EP1204664A1 (en) *	1999-07-28	2002-05-15	Millennium Pharmaceuticals, Inc.	Chemokine receptor antagonists and methods of use therefor
ATE319775T1 (de)	1999-10-20	2006-03-15	Kingspan Holdings Irl Ltd	Zellulärer kunststoff auf basis phenolharz
TW503427B (en)	2000-07-25	2002-09-21	Koninkl Philips Electronics Nv	Display tube comprising a mask with vibration damping means
ES2396186T3 (es) *	2001-11-21	2013-02-19	Millennium Pharmaceuticals, Inc.	Antagonistas de receptores de quimioquinas y métodos de uso de los mismos
DE102011084910A1 (de)	2011-10-20	2013-04-25	Wobben Properties Gmbh	Verfahren und Vorrichtung zum Einspeisen elektrischen Stroms in ein elektrisches Netz

2002
- 2002-11-13 ES ES10012138T patent/ES2396186T3/es not_active Expired - Lifetime
- 2002-11-13 KR KR1020077024914A patent/KR100952767B1/ko not_active Expired - Fee Related
- 2002-11-13 DE DE60209937A patent/DE60209937D1/de not_active Expired - Lifetime
- 2002-11-13 EP EP10012138A patent/EP2286811B1/en not_active Expired - Lifetime
- 2002-11-13 CN CNA2006101054502A patent/CN1911930A/zh active Pending
- 2002-11-13 JP JP2003547392A patent/JP4889920B2/ja not_active Expired - Fee Related
- 2002-11-13 EP EP02789725A patent/EP1448566B3/en not_active Expired - Lifetime
- 2002-11-13 NZ NZ532827A patent/NZ532827A/en not_active IP Right Cessation
- 2002-11-13 PT PT02789725T patent/PT1448566E/pt unknown
- 2002-11-13 NZ NZ585746A patent/NZ585746A/en not_active IP Right Cessation
- 2002-11-13 SI SI200230327T patent/SI1448566T1/sl unknown
- 2002-11-13 KR KR1020107000732A patent/KR101001092B1/ko not_active Expired - Fee Related
- 2002-11-13 CA CA2467672A patent/CA2467672C/en not_active Expired - Fee Related
- 2002-11-13 BR BR0213633-3A patent/BR0213633A/pt not_active Application Discontinuation
- 2002-11-13 KR KR1020047007728A patent/KR100919346B1/ko not_active Expired - Fee Related
- 2002-11-13 DE DE60209937T patent/DE60209937T4/de not_active Expired - Lifetime
- 2002-11-13 PL PL369599A patent/PL217918B1/pl unknown
- 2002-11-13 CN CN02827426.1A patent/CN1585772B/zh not_active Expired - Fee Related
- 2002-11-13 AU AU2002352772A patent/AU2002352772B2/en not_active Ceased
- 2002-11-13 AT AT02789725T patent/ATE320431T1/de active
- 2002-11-13 IL IL16166902A patent/IL161669A0/xx unknown
- 2002-11-13 PL PL403800A patent/PL403800A1/pl unknown
- 2002-11-13 EP EP06004401.3A patent/EP1688418B1/en not_active Expired - Lifetime
- 2002-11-13 SG SG200603354-2A patent/SG165152A1/en unknown
- 2002-11-13 CN CN201410171050.6A patent/CN104031054A/zh active Pending
- 2002-11-13 DK DK02789725T patent/DK1448566T5/da active
- 2002-11-13 ES ES02789725T patent/ES2260497T7/es active Active
- 2002-11-13 SG SG2011011095A patent/SG195393A1/en unknown
- 2002-11-13 NZ NZ596484A patent/NZ596484A/xx not_active IP Right Cessation
- 2002-11-14 TW TW091133354A patent/TWI308568B/zh not_active IP Right Cessation
- 2002-11-14 MY MYPI20024277A patent/MY142646A/en unknown
- 2002-11-14 MY MYPI20064630A patent/MY146601A/en unknown
- 2002-11-14 AR ARP020104390A patent/AR037394A1/es active IP Right Grant
2004
- 2004-04-29 IL IL161669A patent/IL161669A/en not_active IP Right Cessation
- 2004-05-10 ZA ZA200403530A patent/ZA200403530B/xx unknown
- 2004-06-15 NO NO20042500A patent/NO328166B1/no not_active IP Right Cessation
2006
- 2006-06-05 CY CY20061100740T patent/CY1107243T1/el unknown
2007
- 2007-02-06 IL IL181191A patent/IL181191A/en not_active IP Right Cessation
2010
- 2010-05-06 JP JP2010106678A patent/JP2010229136A/ja active Pending
2013
- 2013-04-24 AR ARP130101374A patent/AR090829A2/es unknown
- 2013-05-13 JP JP2013101580A patent/JP5878494B2/ja not_active Expired - Fee Related
2014
- 2014-12-02 JP JP2014244379A patent/JP5936669B2/ja not_active Expired - Fee Related
2016
- 2016-03-01 JP JP2016039332A patent/JP2016138122A/ja active Pending

Also Published As

Publication number	Publication date
MY146601A (en)	2012-08-30
JP2015083577A (ja)	2015-04-30
EP1688418A3 (en)	2008-05-14
CY1107243T1 (el)	2012-11-21
PL217918B1 (pl)	2014-09-30
DE60209937T4 (de)	2009-10-29
ES2396186T3 (es)	2013-02-19
EP1448566B3 (en)	2009-04-08
TW200303197A (en)	2003-09-01
CN1585772A (zh)	2005-02-23
DE60209937D1 (de)	2006-05-11
EP1448566B1 (en)	2006-03-15
IL161669A (en)	2010-12-30
KR100919346B1 (ko)	2009-09-25
BR0213633A (pt)	2004-08-24
JP5878494B2 (ja)	2016-03-08
JP2010229136A (ja)	2010-10-14
NZ596484A (en)	2013-05-31
EP2286811B1 (en)	2012-09-05
JP2013209393A (ja)	2013-10-10
DK1448566T3 (da)	2006-07-31
AU2002352772A1 (en)	2003-06-10
JP4889920B2 (ja)	2012-03-07
MY142646A (en)	2010-12-15
ES2260497T3 (es)	2006-11-01
EP1688418A2 (en)	2006-08-09
ES2260497T7 (es)	2009-11-05
DE60209937T2 (de)	2006-11-30
KR20040064283A (ko)	2004-07-16
JP5936669B2 (ja)	2016-06-22
SG195393A1 (en)	2013-12-30
CN1585772B (zh)	2014-06-04
IL161669A0 (en)	2004-09-27
KR101001092B1 (ko)	2010-12-14
NO328166B1 (no)	2009-12-21
CN104031054A (zh)	2014-09-10
SG165152A1 (en)	2010-10-28
SI1448566T1 (sl)	2006-08-31
AR090829A2 (es)	2014-12-10
NZ532827A (en)	2007-09-28
IL181191A (en)	2012-10-31
ZA200403530B (en)	2005-07-28
PT1448566E (pt)	2006-08-31
AR037394A1 (es)	2004-11-10
KR100952767B1 (ko)	2010-04-14
HK1063789A1 (en)	2005-01-14
CA2467672C (en)	2011-06-28
IL181191A0 (en)	2007-07-04
EP2286811A1 (en)	2011-02-23
JP2005510565A (ja)	2005-04-21
JP2016138122A (ja)	2016-08-04
TWI308568B (en)	2009-04-11
KR20070118146A (ko)	2007-12-13
PL403800A1 (pl)	2013-08-19
KR20100010952A (ko)	2010-02-02
ATE320431T1 (de)	2006-04-15
CA2467672A1 (en)	2003-06-05
AU2002352772B2 (en)	2006-10-26
NZ585746A (en)	2011-12-22
DK1448566T5 (da)	2009-08-03
CN1911930A (zh)	2007-02-14
PL369599A1 (en)	2005-05-02
EP1448566A2 (en)	2004-08-25
EP1688418B1 (en)	2017-03-15
HK1154504A1 (en)	2012-04-27

Publication	Publication Date	Title
IS7041A (is)	2003-11-17	5-HT viðtakabindlar og notkun þeirra
IS8190A (is)	2005-12-21	Ný P2X7 viðtakamótlyf og notkun þeirra
IS7329A (is)	2004-06-21	Flúr setinn sýklóalkanóindól og notkun þeirra semprostaglandín D2 viðtaka mótlyfja
IS7801A (is)	2005-04-14	Púrín efnasambönd og notkun þeirra sem kannabinóíð viðtaka bindla
DK1417175T3 (da)	2013-10-28	Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
NO20040072L (no)	2005-03-08	Nye substituerte benzimidazol-doseringsformer og fremgangsmate for anvendelse av samme
DK2662390T3 (da)	2017-11-06	Interferon alpha receptor 1-antistoffer og anvendelse heraf
NO20013809D0 (no)	2001-08-03	Indolderivater og anvendelse derav som MCP-1 antagonister
EP1541585A4 (en)	2007-12-26	CXCR4 ANTAGONIST AND USE THEREOF
NO20030471D0 (no)	2003-01-30	Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
IL157428A0 (en)	2004-03-28	Bipiperidinyl derivatives and their use as chemokine receptor inhibitors
NO20041008L (no)	2004-03-10	Karbazolderivater og anvendelse derav som NPY5 reseptor antagonister
NO20025762L (no)	2003-01-09	Bicykliske cykloheksylaminer og anvendelse derav som NMDA- reseptorantagonister
NO20031997L (no)	2003-05-02	CRF-reseptor-antagonist og metoder relatert dertil
NO20026103D0 (no)	2002-12-19	1-amino-alkylcycloheksaner som 5-HT3 og neuronal nikotinreseptorantagonister
NO20042500L (no)	2004-06-15	Chemokin-reseptorantagonister og metoder for anvendelse derav
NO20014224D0 (no)	2001-08-31	4-heterocyklysulfonamidyl-6-metoksy-5-(2-metoksy-fenoksy)-2- pyridyl-pyrimidinderivater, fremstilling derav og anvendelse somendotelin reseptor antagonister
NO20043799L (no)	2004-09-10	2-oksasolaminer og deres anvendelse som 5-HT2B reseptor antagonister
NO20033223L (no)	2003-07-16	Histamin-reseptor antagonister
DE60222015D1 (de)	2007-10-04	Ccr-3-rezeptorantagonisten vii
EP1324763A4 (en)	2007-10-31	AGONISTS AND ANTAGONISTS OF STAT3 AND THERAPEUTIC APPLICATIONS THEREOF
NO20035319D0 (no)	2003-11-28	En G-proteinkoblet reseptor og anvendelse derav
AU2003300396A8 (en)	2004-07-22	Chemokine antagonists and uses thereof
DE60209885D1 (de)	2006-05-11	Crf receptor antagonisten
SE0003996D0 (sv)	2000-11-01	Receptorantagonister

Legal Events

Date	Code	Title	Description
2016-06-27	MM1K	Lapsed by not paying the annual fees